Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660112 · ClinicalTrials.gov registry record · Phase 2
(+) Epicatechin to Treat Friedreich's Ataxia
A Phase 2 study, sponsored by Ralitza Gavrilova.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02660112: Completed Phase 2 study, sponsored by Ralitza Gavrilova.
NCT02660112 is a Phase 2 study that has completed, run by Ralitza Gavrilova. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660112, a Phase 2 study, has completed, sponsored by Ralitza Gavrilova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.
Primary Outcome
The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed (8MW), the 9-hole peg test (9HPT), PATA rate (assesses speech speed by repetitions of pronouncing "PaTa" ) and low-contrast letter acuity. FARS is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed
Interventions
- DRUG (+)-Epicatechin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-12-30 |
| Phase | Phase 2 |
What the finished NCT02660112 record still lists
NCT02660112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which (+)-Epicatechin is the first listed.
NCT02660112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660112 about?
NCT02660112 is a clinical study titled "(+) Epicatechin to Treat Friedreich's Ataxia". This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.
What is the current status of trial NCT02660112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-09. Estimated completion is 2018-12-30.
What interventions are being tested in trial NCT02660112?
The interventions under investigation include: (+)-Epicatechin (DRUG).
Who is sponsoring clinical trial NCT02660112?
This trial is sponsored by Ralitza Gavrilova, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02660112's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia